Agilent to build new facility in Colorado, increasing pharmaceutical manufacturing capacity
![](/46/pdcnewsitem/04/22/31/agilent.png)
Expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid APIs.
Agilent Technologies has acquired 20 acres in Weld County, Colorado, on which it plans to build a pharmaceutical manufacturing facility.
The expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid APIs.
"The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases," said Skip Thune, general manager of the company's Nucleic Acids Solutions Division. "At Agilent, we are committed to meeting the ever-increasing needs of our customers for oligonucleotides."
Researchers believe oligonucleotides (short DNA and RNA molecules) hold the potential to treat various forms of cancer, diabetes, muscular dystrophy and other disorders.
Thune noted that the expansion would result in about 150 to 200 new, permanent high-paying jobs.
"Colorado is thrilled to welcome Agilent Technologies to the state," said Gov. John Hickenlooper. "This expansion will enhance Colorado's skilled workforce and dedication to research and development firms. We look forward to supporting Agilent's innovative work in our state."
"The Agilent project is a huge win for the Town of Frederick, Weld County and all of Northern Colorado," said Mike Freeman, chairman of the Weld County Commissioners. "The project adds diversification to our thriving economic base, plus significant new jobs and tax base. It also showcases what an amazing growth region Northern Colorado is due to the diverse workforce and business-friendly environment."
"The impact of new high-paying jobs and millions of dollars in investment will trigger a huge positive ripple through the local economy, pumping new revenue into everything from restaurants to housing," added Tony Carey, mayor of Frederick. "Winning this project shows the tremendous assets of Frederick and Weld County, and we welcome Agilent to our community."
"Local support paved the way for the Agilent project, and it's a great example of local governments working together to proactively accomplish a significant economic development project," said Tom Haren, chairman of the Upstate Colorado Economic Development Board.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance